Laboratory findings.

1<p>Not available.</p>2<p>8:00 am measurement.</p>3<p>Vidia Biomérieux.</p>4<p>Vidas Biomérieux.</p

Genotyping results of BRC TgH41001 strain and 12 reference strains with 15 microsatellite markers.

1<p>PTG is a clone of the ME49 strain; CTG is also known as CEP or C strain; COUGAR is also known as TgCgCa1 or COUG strain; BRC TgH18001 is also known as GUY-DOS or GUY-2001-DOS strain; BRC TgH18002 is also known as GUY-KOE or GUY-2002-KOE strain; BRC TgH18003 is also known as GUY-MAT or GUY-2002-MAT.</p

DataSheet_1_Ophthalmic vascular manifestations in eosinophil-associated diseases: a comprehensive analysis of 57 patients from the CEREO and EESG networks and a literature review.pdf

IntroductionEosinophils have widespread procoagulant effects. In daily practice, eosinophil-related cardiovascular toxicity consists of endomyocardial damage, eosinophilic vasculitis and arterial or venous thrombosis. Here we aim to report on the clinical features and treatment outcomes of patients with unexplained ophthalmic vascular manifestations and eosinophilia.MethodsWe conducted a retrospective, multicenter, observational study and a literature review of patients with eosinophilia (≥0.5 x109/L) and concomitant ophthalmic vascular manifestations independent of the underlying eosinophilic disease but with no alternative cause for ophthalmic manifestations. ResultsFifty-seven patients were included (20 from the observational study and 37 from the literature review). Ophthalmic vascular features were the initial manifestation of eosinophil-related disease in 34 (59%) patients and consisted of 29 central retinal artery occlusions, six branch retinal artery occlusions, five central retinal vein occlusions, two branch retinal vein occlusions, seven retinal vasculitides, two retinal vasospasms, 12 Purtscher’s retinopathies, 13 anterior ischemic optic neuropathies and two posterior ischemic optic neuropathies. The median [IQR] absolute eosinophil count at onset of ophthalmic vascular manifestations was 3.5 [1.7-7.8] x109/L. Underlying eosinophil-related diseases included eosinophilic granulomatosis with polyangiitis (n=32), clonal hypereosinophilic syndrome (HES) (n=1), idiopathic HES (n=13), lymphocytic HES (n=2), adverse drug reactions (n=3), parasitosis (n=2), polyarteritis nodosa (n=1), IgG4-related disease (n=1), eosinophilic fasciitis (n=1) and primary sclerosing cholangitis (n=1). Other extra-ophthalmologic arterial or venous thromboses related to eosinophilia were reported in four (7%) and nine (16%) patients, respectively. Visual prognosis was poor: only eight (10%) patients achieved full recovery of ophthalmologic symptoms. After a median follow-up of 10.5 [1-18] months, one patient (3%) had a recurrence of an ophthalmic vascular manifestation, and three patients (10%) had a recurrence of other vascular symptoms (deep vein thrombosis in two and pulmonary embolism in one patient). At the time of recurrence, absolute eosinophil counts were above 0.5 x109/L in all cases (n=4). DiscussionThis study broadens the spectrum of vascular manifestations associated with hypereosinophilia by adding ophthalmic vascular manifestations. In patients with ophthalmological vascular manifestations and hypereosinophilia, aggressive treatment of the underlying pathology (and normalization of blood count) should be implemented.</p

Kaplan-Meier plots of the risk of disease relapse following rituximab for patients with IgG4-RD RI >9 and with IgG4-RD RI ≤9 at RTX treatment.

<p>IgG4-RD RI, IgG4-related disease Responder Index.</p

Clinical, biological and radiological efficacy of RTX in 33 patients with IgG4-RD.

<p>Clinical, biological and radiological efficacy of RTX in 33 patients with IgG4-RD.</p

Kaplan-Meier plots of the risk of disease relapse following rituximab in 31 IgG4-RD responding patients.

<p>Kaplan-Meier plots of the risk of disease relapse following rituximab in 31 IgG4-RD responding patients.</p

Hazard ratio for risk of flare: Unadjusted Cox regressions.

<p>Hazard ratio for risk of flare: Unadjusted Cox regressions.</p

Kaplan-Meier plots of the risk of disease relapse following rituximab for patients with IgG4-RD RI >9 and with IgG4-RD RI ≤9 at RTX treatment.

<p>IgG4-RD RI, IgG4-related disease Responder Index.</p

Risk of disease relapse following rituximab for patients with glucocorticoid and without glucocorticoid maintenance therapy at last follow-up or relapse.

<p>Risk of disease relapse following rituximab for patients with glucocorticoid and without glucocorticoid maintenance therapy at last follow-up or relapse.</p